Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19
- PMID: 32940328
- PMCID: PMC7797721
- DOI: 10.1093/pubmed/fdaa170
Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19
Abstract
Background: The recent pandemic by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global emergency. There is large number of asymptomatic cases of SARS-CoV-2 that are not reported. Hence, serological evidence of SARS-CoV2 antibodies is warranted for a better estimation of the actual number of infected patients to limit the disease spread and to get an idea of herd immunity.
Methods: This is a cross-sectional study conducted from May 2020 to July 2020 at National Institute of Blood Diseases at Pakistan. The study includes healthcare workers (HCWs), community and industrial workers. The anti-SARS-CoV-2 test was performed by electrochemiluminescence immunoassay analyzer.
Results: A total of 1675 samples have been received from three groups of population. The percentage positivity for industrial employees is high (50.3%) for HCW (13.2%) and community population (34%).Total percentage for positive antibodies result is ~36%.
Conclusion: Our seroprevalence is 36%, which still far from herd immunity that needs to be at least 60-70% in population. If we consider acquiring 60% seroprevalence in next few months, then herd immunity is not far from reality, provided the antibodies did not decline with time. Although the current study is based on a small sample of participants, the findings suggest a study with larger population to implement stronger and targeted interventions.
Keywords: infectious disease; public health.
© The Author(s) 2020. Published by Oxford University Press on behalf of Faculty of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures
Similar articles
-
Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.Lancet. 2021 Mar 20;397(10279):1075-1084. doi: 10.1016/S0140-6736(21)00238-5. Lancet. 2021. PMID: 33743869 Free PMC article.
-
SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?Infection. 2021 Oct;49(5):983-988. doi: 10.1007/s15010-021-01629-2. Epub 2021 May 25. Infection. 2021. PMID: 34032997 Free PMC article. Clinical Trial.
-
SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.Microbiol Spectr. 2021 Oct 31;9(2):e0039121. doi: 10.1128/Spectrum.00391-21. Epub 2021 Sep 29. Microbiol Spectr. 2021. PMID: 34585976 Free PMC article.
-
Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review.PLoS One. 2021 Apr 2;16(4):e0248946. doi: 10.1371/journal.pone.0248946. eCollection 2021. PLoS One. 2021. PMID: 33798211 Free PMC article.
-
Current challenges of severe acute respiratory syndrome coronavirus 2 seroprevalence studies among blood donors: A scoping review.Vox Sang. 2022 Apr;117(4):476-487. doi: 10.1111/vox.13221. Epub 2021 Dec 3. Vox Sang. 2022. PMID: 34862614
Cited by
-
Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study.Epidemiol Infect. 2021 May 18;149:e130. doi: 10.1017/S0950268821001163. Epidemiol Infect. 2021. PMID: 34001292 Free PMC article.
-
Humoral and T cell responses to SARS-CoV-2 reveal insights into immunity during the early pandemic period in Pakistan.BMC Infect Dis. 2023 Dec 1;23(1):846. doi: 10.1186/s12879-023-08829-1. BMC Infect Dis. 2023. PMID: 38041026 Free PMC article.
-
SerumCovid database: Description and preliminary analysis of serological COVID-19 diagnosis in healthcare workers.PLoS One. 2022 Mar 17;17(3):e0265016. doi: 10.1371/journal.pone.0265016. eCollection 2022. PLoS One. 2022. PMID: 35298515 Free PMC article.
-
Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan.Int J Infect Dis. 2021 May;106:176-182. doi: 10.1016/j.ijid.2021.03.040. Epub 2021 Mar 15. Int J Infect Dis. 2021. PMID: 33737137 Free PMC article.
-
Dynamics of SARS-CoV-2 Immunoglobulin G Antibody Among Hospitalized Patients and Healthcare Workers During the Delta Wave in Bangladesh.Cureus. 2025 Apr 13;17(4):e82175. doi: 10.7759/cureus.82175. eCollection 2025 Apr. Cureus. 2025. PMID: 40370886 Free PMC article.
References
-
- Unhale SS, Ansar QB, Sanap S et al. . A review on corona virus (Covid-19). World J Pharm Life Sci 2020;6(4):109–15.
-
- Rodriguez-Morales AJ, Bonilla-Aldana DK, Tiwari R et al. . COVID-19, an emerging coronavirus infection: current scenario and recent developments-an overview. J Pure Appl Microbiol 2020;14:6150.
-
- Cascella M, Rajnik M, Cuomo A et al. . Features, Evaluation and Treatment Coronavirus (COVID-19) In Statpearls [internet] StatPearls Publishing, 2020. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous